These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 20405290)

  • 41. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
    Serebruany VL; Eisert C; Sabaeva E; Makarov L
    Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
    Newland A
    Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
    Rodeghiero F; Pecci A; Balduini CL
    J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombopoietin: too much or too little.
    Newland A
    Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
    Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
    Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
    Vibor M; Rogulj IM; Ostojic SK
    Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
    Siegal D; Crowther M; Cuker A
    Semin Hematol; 2013 Jan; 50 Suppl 1(0 1):S18-21. PubMed ID: 23664510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J; Kaider A; Pabinger I; Panzer S
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New therapeutic options for immune thrombocytopenia.
    Schipperus M; Fijnheer R
    Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
    Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.